Protagonist Therapeutics (PTGX) Stock Price, News & Analysis

Company Overview

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease. PTG-200, a selective interleukin-23 receptor antagonist, is in Phase 2 clinical trials for moderate to severe Crohn’s disease. The company’s PTG-300 program is a hepcidin mimetic being evaluated in hematologic disorders characterized by iron overload, including polycythemia vera and myelofibrosis.

Founded in 2006 and headquartered in San Diego, California, Protagonist Therapeutics conducts global clinical trials across North America, Europe and Asia. The company is led by a team of seasoned biotechnology executives with deep expertise in peptide drug discovery and development. Protagonist maintains collaborations with academic institutions and industry partners to advance its pipeline and explore additional therapeutic areas where oral peptide therapeutics may deliver significant patient benefit.

Key Stats

• Today's Range: $98.95 to $105.03
• 50-Day Range: $87.10 to $105.98
• 52-Week Range: $41.28 to $107.84
• Volume: 989,856 shs
• Average Volume: 657,779 shs
• Market Capitalization: $6.69 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $113.69
• Consensus Rating: Moderate Buy

Protagonist Therapeutics Stock Analysis - MarketRank™

Protagonist Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 663rd out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Protagonist Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for Protagonist Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Protagonist Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Protagonist Therapeutics are expected to decrease in the coming year, from $1.02 to ($1.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Protagonist Therapeutics is -50.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Protagonist Therapeutics is -50.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Protagonist Therapeutics has a P/B Ratio of 10.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.84% of the float of Protagonist Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Protagonist Therapeutics has a short interest ratio ("days to cover") of 11.61, which indicates bearish sentiment.

Change versus previous month

Short interest in Protagonist Therapeutics has recently decreased by 2.66%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Protagonist Therapeutics does not currently pay a dividend.

Dividend Growth

Protagonist Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.88

News Sentiment

Protagonist Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Protagonist Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for PTGX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,539,786.00 in company stock.

Percentage Held by Insiders

4.90% of the stock of Protagonist Therapeutics is held by insiders.

Percentage Held by Institutions

98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PTGX Stock Analysis - Frequently Asked Questions

How have PTGX shares performed this year?

Protagonist Therapeutics' stock was trading at $87.34 on January 1st, 2026. Since then, PTGX shares have increased by 19.0% and is now trading at $103.97.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) released its quarterly earnings results on Wednesday, February, 25th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by $0.16. The company earned $7.44 million during the quarter, compared to analysts' expectations of $14.92 million. Protagonist Therapeutics had a negative trailing twelve-month return on equity of 19.89% and a negative net margin of 282.83%.

When did Protagonist Therapeutics IPO?

Protagonist Therapeutics (PTGX) raised $90 million in an IPO on Wednesday, August 10th 2016. The company issued 7,500,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' top institutional investors include Jennison Associates LLC (1.67%), Pictet Asset Management Holding SA (0.91%), Principal Financial Group Inc. (0.57%) and Bank of New York Mellon Corp (0.53%). Insiders that own company stock include Dinesh V Ph D Patel, Suneel Gupta, Arturo Md Molina, Harold E Selick, Asif Ali, William D Waddill and Lewis T Williams.
View institutional ownership trends.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Protagonist Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AUO (AUOTY).

Company Calendar

• Last Earnings: 2/25/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PTGX
• CIK: 1377121
• Web: www.protagonist-inc.com
• Phone: (510) 474-0170
• Fax: N/A
• Employees: 120
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Protagonist Therapeutics: $113.69
• High Price Target: $137.00
• Low Price Target: $82.00
• Potential Upside/Downside: +9.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 101.93
• P/E Growth: N/A
• Net Income: -$130.15 million
• Net Margins: -282.83%
• Pretax Margin: -281.01%
• Return on Equity: -19.89%
• Return on Assets: -18.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.71
• Quick Ratio: 12.71

Sales & Book Value

• Annual Sales: $46.02 million
• Price / Sales: 145.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.83 per share
• Price / Book: 10.58

Miscellaneous

• Outstanding Shares: 64,310,000
• Free Float: 61,154,000
• Market Cap: $6.69 billion
• Optionable: Optionable
• Beta: 1.89